U.S. flag

An official website of the United States government

NM_001495.5(GFRA2):c.725C>T (p.Ser242Phe) AND Pazopanib response

Germline classification:
drug response (1 submission)
Last evaluated:
Jul 16, 2015
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000190397.2

Allele description [Variation Report for NM_001495.5(GFRA2):c.725C>T (p.Ser242Phe)]

NM_001495.5(GFRA2):c.725C>T (p.Ser242Phe)

Gene:
GFRA2:GDNF family receptor alpha 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
8p21.3
Genomic location:
Preferred name:
NM_001495.5(GFRA2):c.725C>T (p.Ser242Phe)
HGVS:
  • NC_000008.11:g.21750657G>A
  • NG_029215.1:g.43178C>T
  • NG_029215.2:g.43178C>T
  • NM_001165038.2:c.410C>T
  • NM_001165039.2:c.326C>T
  • NM_001495.5:c.725C>TMANE SELECT
  • NP_001158510.1:p.Ser137Phe
  • NP_001158511.1:p.Ser109Phe
  • NP_001486.4:p.Ser242Phe
  • NC_000008.10:g.21608169G>A
Protein change:
S109F
Links:
dbSNP: rs796065050
NCBI 1000 Genomes Browser:
rs796065050
Molecular consequence:
  • NM_001165038.2:c.410C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001165039.2:c.326C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001495.5:c.725C>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Pazopanib response
Identifiers:
MedGen: CN232333

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000243887Center for Personalized Medicine, Roswell Park Cancer Institute
no assertion criteria provided
drug response
(Jul 16, 2015)
Condition: Pazopanib response
Drug reported used for: malignant granular cell tumor
somaticcase-control

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedsomaticyesnot providednot providednot providednot providednot providedcase-control

Details of each submission

From Center for Personalized Medicine, Roswell Park Cancer Institute, SCV000243887.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcase-controlnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1somaticyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Apr 23, 2022